Table 1.
Patient, tumour and treatment characteristics for effective treatment.
| 5-fractions schedule (N = 106) | 15-fractions schedule (N = 94) | Sign. | |
|---|---|---|---|
| Patient characteristics | |||
| Age, years | p = 0.3 | ||
| Median | 59 | 62 | |
| Range | 37–83 | 26–84 | |
| <40 | 3 (2.8%) | 5 (5.3%) | |
| 40-49 | 10 (9.4%) | 10 (10.6%) | |
| 50-59 | 41 (38.7%) | 25 (26.6%) | |
| 60-69 | 34 (32.1%) | 40 (42.6%) | |
| 70-79 | 16 (15.1%) | 11 (11.7%) | |
| ≥80 | 2 (1.9%) | 3 (2.8%) | |
| Body Mass Index (BMI) | p = 0.05 | ||
| Median | 25.0 | 25.6 | |
| <20 | 6 (5.7%) | 12 (12.8%) | |
| 20-25 | 47 (44.3%) | 28 (29.8%) | |
| >25 | 53 (50%) | 54 (57.4%) | |
| Breast volume (mean) | 472.30 C C | 489.77 C C | p = 0.9 |
| Smoking behaviour | p = 0.6 | ||
| Current | 9 (8.5%) | 12 (12.8%) | |
| Former | 26 (24.5%) | 24 (25.5%) | |
| Never | 71 (67.0%) | 58 (61.7%) | |
| Alcohol use | p = 0.4 | ||
| Current | 72 (67.9%) | 71 (75.5%) | |
| Former | 6 (5.7%) | 6 (6.4%) | |
| Never | 28 (26.4%) | 17 (18.1%) | |
| Tumour characteristics | |||
| Tumour side | p = 0.5 | ||
| Left | 53 (50.0%) | 42 (44.7%) | |
| Right | 53 (50.0%) | 52 (55.3%) | |
| Tumour location | p = 0.6 | ||
| Lower-inner quadrant | 12 (12%) | 12 (13%) | |
| Lower-outer quadrant | 12 (12%) | 17 (18%) | |
| Upper-inner quadrant | 18 (17%) | 9 (9%) | |
| Upper-outer quadrant | 47 (44%) | 42 (44%) | |
| Central portion of the breast | 17 (16%) | 16 (17%) | |
| Histological grade | p = 0.6 | ||
| Poor | 23 (22%) | 21 (22%) | |
| Moderate | 65 (61%) | 52 (55%) | |
| Well | 18 (17%) | 21 (22%) | |
| Histological type | p = 0.6 | ||
| DCIS | 5 (5%) | 8 (8%) | |
| Infiltrating lobular | 10 (10%) | 8 (8%) | |
| Infiltrating ductal | 86 (81%) | 72 (77%) | |
| Tubular | 1 (1%) | 3 (3%) | |
| Other | 4 (4%) | 3 (3%) | |
| Pathological tumour size | p = 0.5 | ||
| Mean | 15 mm (SD 6.2) | 11 mm (SD 7.7) | |
| Range | 1–26 mm | 1–35 mm | |
| Ki 67 | p = 0.9 | ||
| <20% | 53 (50.0%) | 48 (51.1%) | |
| ≥20% | 41 (38.7%) | 34 (36.2%) | |
| Unknown | 12 (11.3%) | 12 (12.8%) | |
| HER-2 Immunohistochemistry | p = 0.5 | ||
| Negative | 43 (40.6%) | 34 (36.2%) | |
| Positive: 1+ | 21 (19.8%) | 28 (29.8%) | |
| Positive: 2+ | 17 (16.0%) | 15 (16.0%) | |
| Positive: 3+ | 7 (6.6%) | 3 (3.2%) | |
| Unknown | 18 (17.0%) | 14 (14.9%) | |
| FISH/SISH/CISH | p = 0.3 | ||
| Amplification | 11 (10.4%) | 6 (6.4%) | |
| No amplification | 41 (38.7%) | 46 (48.9%) | |
| Unknown | 54 (50.9%) | 42 (44.7%) | |
| ER status | p = 0.7 | ||
| Positive (>1%) | 75 (70.8%) | 63 (67.0%) | |
| Negative (≤1%) | 10 (9.4%) | 12 (12.8%) | |
| Unknown | 21 (19.8%) | 19 (20.2%) | |
| PR status | p = 1.0 | ||
| Positive (>5%) | 69 (65.1%) | 61 (64.9%) | |
| Negative (≤5%) | 16 (15.1%) | 14 (14.9%) | |
| Unknown | 21 (19.8%) | 19 (20.2%) | |
| cTNM | p = 0.5 | ||
| T1N0M0 | 90 (85%) | 78 (83%) | |
| T1N1M0 | 0 (0%) | 1 (1%) | |
| T2N0M0 | 11 (10%) | 7 (7%) | |
| TisN0M0 | 5 (5%) | 8 (9%) | |
| pTNM | p = 0.5 | ||
| T1N0M0 | 86 (81%) | 77 (82%) | |
| T1N1 (mi)M0 | 4 (4%) | 2 (2%) | |
| T2N0M0 | 11 (10%) | 7 (7%) | |
| TisN0M0 | 5 (5%) | 8 (9%) | |
| Treatment characteristics | |||
| Surgery | |||
| Type of surgery | p = 0.8 | ||
| Segmentectomy/quadrantectomy | 4 (3.8%) | 3 (3.2%) | |
| Wide local excision | 102 (96.2%) | 91 (96.8%) | |
| Axillary surgery | p = 0.09 | ||
| Axillary clearance | 0 (0.0%) | 1 (1.1%) | |
| Sentinel node biopsy | 94 (88.7%) | 87 (92.6%) | |
| No axillary surgery | 12 (11,3%) | 6 (6.4%) | |
| Postoperative haematoma | p = 05 | ||
| Yes | 12 (11.3%) | 11 (11.7%) | |
| No | 90 (84.9%) | 83 (88.3%) | |
| Unknown | 4 (3.8%) | 0 (0.0%) | |
| Postoperative edema | p = 0.9 | ||
| Yes | 5 (4.7%) | 4 (4.3%) | |
| No | 99 (93.4%) | 88 (93.6%) | |
| Unknown | 2 (1.9%) | 2 (2.1%) | |
| Postoperative infection | p = 0.6 | ||
| Yes | 5 (4.7%) | 6 (6.4%) | |
| No | 98 (92.5%) | 87 (92.6%) | |
| Unknown | 3 (2.8%) | 1 (1.1%) | |
| Delayed wound healing | p = 0.2 | ||
| Yes | 0 (0.0%) | 4 (4.3%) | |
| No | 103 (97.2%) | 89 (94.7%) | |
| Unknown | 3 (2.8%) | 1 (1.1%) | |
| Chemotherapy | |||
| Neoadjuvant chemotherapy | p = 0.9 | ||
| Yes | 4 (3.8%) | 4 (4.3%) | |
| No | 102 (96.2%) | 90 (95.7%) | |
| Adjuvant chemotherapy | p = 0.7 | ||
| Yes | 27 (25.5%) | 22 (23.4%) | |
| No | 79 (74.5%) | 72 (76.6%) | |
| Hormone therapy | p = 0.9 | ||
| Tamoxifen | 48 (45.3%) | 46 (48.9%) | |
| Aromatase inhibitor | 34 (32.1%) | 29 (30.9%) | |
| None | 24 (22.6%) | 19 (20.2) | |
| Targeted therapy with trastuzumab | p = 0.3 | ||
| Yes | 11 (10.4%) | 6 (6.4%) | |
| No | 95 (89.6%) | 88 (93.6%) | |
| Radiotherapy | |||
| Simultaneous integrated boost | 95 (90.5%) | 85 (90.4%) | p = 1.0 |
| DIBH | 2 (1.9%) | 2 (2.1%) | p = 0.9 |
| Position | p = 0.3 | ||
| Prone | 101 (95.3%) | 91 (96.8%) | |
| Supine | 5 (4.7%) | 3 (3.2%) | |
| Overall treatment time (mean) | 10.6 days (SD 0.8) | 21.6 days (SD 1.3) | |
BMI: body mass index, DCIS: ductal carcinoma in situ, HER2: human epidermal growth factor receptor 2.
ER: estrogen receptor, PR: progesterone receptor, DIBH: deep inspiration breath hold.